CSPC Innovation files for H share listing on stock exchange

CSPC Pharmaceutical Group Limited announced that its indirect subsidiary, CSPC Innovation Pharmaceutical Co., Ltd., submitted a listing application for a proposed H share listing to the Stock Exchange on December 10, 2025. This move is part of a discloseable transaction previously referenced in the company’s announcement dated September 30, 2025. CSPC Innovation is expected to remain an indirect subsidiary of the company post-listing.

The completion of the proposed H share listing is contingent upon various factors, including the fulfillment of filing procedures with, and approvals from, relevant governmental and regulatory authorities such as the CSRC, the Stock Exchange, and the SFC. The company intends to provide further updates as the process progresses. Shareholders and potential investors are advised that the listing is not guaranteed and its timing is subject to change.

A redacted application proof of CSPC Innovation’s listing document is available on the Stock Exchange’s website, containing business and financial information. This document is in draft form, incomplete, and subject to material changes, and therefore, investors should exercise caution.